Kentaro Matsuzaki

Dr. Kentaro Matsuzaki

Department of Environmental Physiology, Faculty of Medicine, Shimane University, 89-1 Enya-cho, Izumo 693-8501, Japan
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2008 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
HOHiroshi Onozuka
Hiroshi Onozuka
ANAkira Nakajima
Akira Nakajima
Kentaro MatsuzakiKentaro Matsuzaki
Kentaro Matsuzaki
RSRyong-Woon Shin
Ryong-Woon Shin
KOKoichi Ogino
Koichi Ogino
YOYasushi Ohizumi
Yasushi Ohizumi
Increasing evidence suggests that the elevation of β-amyloid (Aβ) peptides in the brain is central to the pathogenesis of Alzheimer9s disease (AD). Our recent studies have demonstrated that nobiletin, a polymethoxylated flavone from citrus peels, enhances cAMP/protein kinase A/extracellular signal-regulated kinase/cAMP response element-binding protein signaling in cultured hippocampal neurons and ameliorates Aβ-induced memory impairment in AD model rats. For the first time, we report that this natural compound improves memory deficits in amyloid precursor protein (APP) transgenic mice that overexpress human APP695 harboring the double Swedish and London mutations [APP-SL 7-5 transgenic (Tg) mice]. Our enzyme-linked immunosorbent assay (ELISA) also showed that administration of nobiletin to the transgenic mice for 4 months markedly reduced quantity of guanidine-soluble Aβ1–40 and Aβ1–42 in the brain. Furthermore, consistent with the results of ELISA, by immunohistochemistry with anti-Aβ antibody, it was evidently shown that the administration of nobiletin decreased the Aβ burden and plaques in the hippocampus of APP-SL 7-5 Tg mice. These findings suggest that this natural compound has potential to become a novel drug for fundamental treatment of AD.

4 July 2016 in Critical Reviews in Biotechnology
Verified
Journal Article
Open access
MHMichio Hashimoto
Michio Hashimoto
SHShahdat Hossain
Shahdat Hossain
AMAbdullah Al Mamun
Abdullah Al Mamun
Kentaro MatsuzakiKentaro Matsuzaki
Kentaro Matsuzaki
HAHiroyuki Arai
Hiroyuki Arai
Docosahexaenoic acid (DHA, C22:6, ω-3) is a highly polyunsaturated omega-3 fatty acid. It is concentrated in neuronal brain membranes, for which reason it is also referred to as a “brain food”. DHA is essential for brain development and function. It plays an important role in improving antioxidant and cognitive activities of the brain. DHA deficiency occurs during aging and dementia, impairs memory and learning, and promotes age-related neurodegenerative diseases, including Alzheimer’s disease (AD). For about two decades, we have reported that oral administration of DHA increases spatial memory acquisition, stimulates neurogenesis, and protects against and reverses memory impairment in amyloid β peptide-infused AD rat models by decreasing amyloidogenesis and protects against age-related cognitive decline in the elderly. These results demonstrate a robust link between DHA and cognitive health. Rodents that were fed a diet low in ω-3 polyunsaturated fatty acids, particularly those that were DHA-deficient, frequently suffered from anxiety, depression and memory impairment. Although the exact mechanisms of action of DHA in brain functions are still elusive, a host of mechanisms have been proposed. For example, DHA, which inherently has a characteristic three-dimensional structure, increases membrane fluidity, strengthens antioxidant activity and enhances the expression of several proteins that act as substrates for improving memory functions. It reduces the brain amyloid burden and inhibits in vitro fibrillation and amyloid-induced neurotoxicity in cell-culture model. In this review, we discuss how DHA acts as a molecule with diverse functions.

1 June 2006 in Neuroscience Letters
Verified
Journal Article
Closed access
Kentaro MatsuzakiKentaro Matsuzaki
Kentaro Matsuzaki
TYTohru Yamakuni
Tohru Yamakuni
MHMichio Hashimoto
Michio Hashimoto
AHAbdul Md. Haque
Abdul Md. Haque
OSOsamu Shido
Osamu Shido
YOYasushi Ohizumi
Yasushi Ohizumi

1 May 2009 in Neuroscience
Verified
Journal Article
Closed access
MKMasanori Katakura
Masanori Katakura
MHM. Hashimoto
M. Hashimoto
HSH.M. Shahdat
H.M. Shahdat
SGS. Gamoh
S. Gamoh
TOT. Okui
T. Okui
OSO. Shido
O. Shido

27 September 2005 in Biochemistry
Verified
Journal Article
Closed access
HNHiroyuki Nagase
Hiroyuki Nagase
TYTohru Yamakuni
Tohru Yamakuni
Kentaro MatsuzakiKentaro Matsuzaki
Kentaro Matsuzaki
YMYuji Maruyama
Yuji Maruyama
JKJiro Kasahara
Jiro Kasahara
YOYasushi Ohizumi
Yasushi Ohizumi

1 January 2008 in European Journal of Pharmacology
Verified
Journal Article
Closed access
Kentaro MatsuzakiKentaro Matsuzaki
Kentaro Matsuzaki
KMKenichi Miyazaki
Kenichi Miyazaki
SSSeiichiro Sakai
Seiichiro Sakai
HYHiromu Yawo
Hiromu Yawo
NNNorihito Nakata
Norihito Nakata
YOYasushi Ohizumi
Yasushi Ohizumi